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Abstract
Objective: This study assessed the accuracy of real-time continuous glucose monitoring system (RTCGMS) devices in an
intensive care unit (ICU) to determine whether the septic status of the patient has any influence on the accuracy of the
RTCGMS.
Subjects and Methods: In total, 41 patients on insulin therapy were included. Patients were monitored for 72 h using
RTCGMS. Arterial blood glucose (ABG) samples were obtained following the protocol established in the ICU. The results
were evaluated using paired values (excluding those used for calibration) with the performance assessed using numerical
accuracy. Nonparametric tests were used to determine statistically significant differences in accuracy.
Results: In total, 956 ABG/RTCGMS pairs were analyzed. The overall median relative absolute difference (RAD) was 13.5%,
and the International Organization for Standardization (ISO) criteria were 68.1%. The median RADs reported for patients
with septic shock, with sepsis, and without sepsis were 11.2%, 14.3%, and 16.3%, respectively (P < 0.05). Measurements
meeting the ISO criteria were 74.5%, 65.6%, and 63.7% for patients with septic shock, with sepsis, and without sepsis,
respectively (P < 0.05).
Conclusions: The results showed that the septic status of patients influenced the accuracy of the RTCGMS in the ICU. Accuracy
was significantly better in patients with septic shock in comparison with the other patient cohorts.
Introduction
Hyperglycemia is a common phenomenon in critically illpatients, and one that has been shown to be associated
with a worse prognosis.1–4 Such effects can be explained by
different phenomena.5–9 For this reason the management of
glycemia in intensive care unit (ICU) patients has been the
focus ofmultiple studies. One aim of some of these studies has
been to define the target range within which the patients’
blood glucose (BG) must be maintained in order to improve
their prognosis. Although some studies have claimed that the
strict control of glycemia (80–110mg/dL) significantly de-
creases themorbidity andmortality of critically ill patients,10–13
such a tight target is also associated with an increase in
hypoglycemia. Other studies14–16 have indicated that a less
strict range helps avoid the risk of hypoglycemia without an
increase in mortality.
While it is still being debated what the target for glycemic
control should be, what is not in question is the need to
manage glycemia in critically ill patients. In ICUs, BG moni-
toring is performed intermittently using different bedside BG
meters, which imposes an additional burden on the ICU staff.
Continuous glucose monitoring would allow for better con-
trol of glycemia by identifying real-time (RT) fluctuations in
BG and allow the staff to anticipate episodes of hyper- and
hypoglycemia, potentially with fewer manual measurements.
Previous studies have evaluated the accuracy of continu-
ous glucose monitoring system (CGMS) devices in critically ill
patients.17–27 Some of these clinical trials in the ICU have re-
ported that the CGMS glucose values were accurate com-
pared with BG measurements.17,22,24,26,27 Other studies have
concluded that although the CGMS could be clinically useful
in the ICU, it is not sufficiently accurate and reliable at present
to be used for therapeutic decisions.18–20,21,23 In contrast, one
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study indicated that although the CGMS gave accurate re-
sults, a high rate of underestimation of hypoglycemia made
this device unreliable in the ICU.25
Several authors have described, in general terms, the
methods currently accepted tomeasure the accuracy of CGMS
devices.28,29 The accuracy of these devices can be determined
using the mean and median relative absolute difference
(RAD) values between the CGMS measurements and BG
measurements,28 as well as by the International Organization
for Standardization (ISO) criteria.30
The aims of this study were to assess the accuracy, in a
mixed ICU, of the Guardian REAL-Time CGMS (RTCGMS)
(Medtronic, Northridge, CA) and to determine whether the
septic status of the patient, considering different degrees of
sepsis,31 has any influence on the accuracy of the RTCGMS. In
particular, tissue perfusion is impaired in patients with septic
shock, a condition that may influence the relationship be-
tween BG and interstitial glucose. The accuracy of the
RTCGMS was assessed using numerical accuracy criteria.
The results of this study were presented, in part, at the 23rd
European Society of Intensive Care Medicine Annual Con-
gress32 and the 4th International Conference on Advanced
Technologies & Treatments for Diabetes.33
Subjects and Methods
Patients and setting
Forty-one patients (14 medical, 21 surgical, and six trauma
patients) admitted to an 18-bedmixed ICU at the Doctor Josep
Trueta Hospital (Girona, Spain) were included in a prospec-
tive observational study (Acute Physiology And Chronic
Health Evaluation [APACHE] II score, 18.0 [range, 14.3–21.8];
SOFA score, 8.5 [6–10]). Of these 41 patients, 38 received se-
dation and mechanical ventilation. The characteristics of the
patients are listed in Table 1.
This study included patients who presented with hyper-
glycemia and needed intravenous insulin therapy on admis-
sion to the ICU. According to the glycemic control protocol
established in our ICU, based on the insulin infusion protocol
described by Goldberg et al.,34 a continuous infusion of in-
travenous insulin was started once the patient had BG values
above 150mg/dL to maintain the BG between 120 and
160mg/dL. Short-acting insulin (Actrapid, Novo Nordisk,
Bagsværd, Denmark) diluted in 0.9% NaCl was used. In-
travenous insulin therapy was stopped when the BG was
below 110mg/dL. The other selection criteria included the
following: admission to the ICU, above 18 years of age, ad-
ministration of artificial nutrition (parenteral, enteral, or
mixed) as the only form of nutritional support, APACHE II
score of > 12, and having an arterial blood catheter because of
their clinical condition. Patients younger than 18 years,
pregnant women, and patients who had participated in an-
other trial were excluded.
Under continuous glucose monitoring, the septic status of
the patient was recorded every 24 h by the patient’s medical
team. Septic status was classified based on the definitions of
the American College of Chest Physicians and the Society of
Critical CareMedicine Consensus Conference Committee31 in
three groups: patients without sepsis, patients with sepsis,
and patients with septic shock. Patients with septic shock
were defined as those patients with poor tissue perfusion after
a correct resuscitation, according to the guidelines for the
management of sepsis,35 and/or with vasoconstrictor ther-
apy. Cardiogenic, hemorrhagic, and anaphylactic causes of
shock were ruled out. The use of glucocorticoids and the fluid
balance were not recorded. The protocol was approved by the
Ethics Committee of the Doctor Josep Trueta Hospital. All of
the patients gave informed consent, either signed by them if
they were conscious and capacitated or signed by family
members in cases of unconscious patients.
Glucose monitoring system
The patients were monitored for 72 h using the RTCGMS
(MiniMed reference CSS72). Gold standard data were ob-
tained through arterial BG (ABG) samples following the gly-
cemic control protocol established in the ICU. When a patient
showed high glycemic instability (hyper- and hypoglycemia),
ABG samples were taken every 30min. Then, if glycemic
values were stabilized, ABG measurements were spaced to
every 1, 2, 3, and until every 4 h. If the patient’s nutritional
intake was stopped for any reason, the glycemic control
testing was performed more frequently, even during nor-
moglycemia. ABG was measured using the whole BG
concentration reported by the HemoCue 201 DM system
(HemoCue AB, A¨ngelholm, Sweden). Quality control checks
were performed using liquid controls recommended in He-
moCue’s instructions. Additional ABG measurements were
used for RTCGMS calibration.
The RTCGMS consists of a disposable subcutaneous
needle-type sensor and an external monitor. The sensor is an
amperometric system that uses glucose oxidase, which gen-
erates an electric current proportional to the glucose concen-
tration in the interstitial fluid.36 The sensor measures
interstitial glucose every 10 s and records the mean values at
5-min intervals. The RTCGMS was placed in the subcutane-
ous tissue of the upper leg of each patient. This sensor location
Table 1. Baseline Characteristics, Primary
Conditions, and Outcomes
of All Patients Included in the Study
Variable Overall
Number (%) 41 (100)
Type of critically ill patients
(medical/surgical/trauma) (%)
14/21/6
(34.2/51.2/14.6)
Age (years) 63.6 – 11.0
Sex (female/%) 17/41.5
Body mass index (kg/m2) 32.2 – 6.6
Previously known diabetes (yes/%) 19/46.3
Stay in ICU (days) 24.4 – 19.8
Stay in the hospital (days) 41.5 – 31.9
ICU mortality (yes/%) 10/24.4
Hospital mortality (yes/%) 13/31.7
Sequential organ failure assessmenta 8.3 – 3.3
Acute Physiology And
Chronic Health Evaluation score IIa
18.8 – 5.6
Sepsis (yes/%)a 31/75.6
Mechanical ventilation (yes/%) 38/92.7
CVVHDF (yes/%) 3/7.3
Nutrition (enteral/parenteral) 25/16
Data are expressed as mean– SD values.
aThese values correspond to the initial condition of the patient.
CVVHDF, continuous venovenous hemodiafiltration; ICU, inten-
sive care unit.
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was used because of the difficulty of placement in other lo-
cations. It was not feasible to locate the sensor on either chest,
the abdomen, or the buttocks because critically ill patients
were usually subject to chest X-ray and laparatomies, and
most of them were in the supine position. After electrode in-
sertion, the sensor was directly connected to the MiniLink
REAL-Time transmitter (Medtronic). Following a 2-h initial-
ization period, the first ABG measurement was used for
RTCGMS calibration. These calibrations were performed ac-
cording to the RTCGMS manufacturer’s instructions (three to
four per day).37
ABG values were used by the nurses to administer insulin
therapy, according to the protocol established by the hospital.
RTCGMS readings were not used to modify insulin therapy.
After the third day, the RTCGMS and ABG data were
downloaded to a computer using Medtronic Carelink Pro
version 2.0B and HemoCue 201 DM version 3.1 software,
respectively.
The accuracy of the RTCGMS in this study was evaluated
using paired values (ABG/RTCGMS), excluding those used
for calibration. Because the ABG and RTCGMS readings were
obtained at different times, the RTCGMS readings were
matched to the reference ABG within – 2.5min.38
Accuracy metrics and statistical analysis methods
Descriptive statistics of demographic and clinical variables
included the mean and SD values for quantitative variables
and percentages for qualitative variables. Furthermore, de-
scriptive statistics (mean [SD] and median [interquartile
range]) were calculated by all RTCGMS and ABG measure-
ments (including those used for calibration), respectively.
The accuracy criteria currently accepted by the U.S. Food
and Drug Administration for CGMS statistics are the Pearson
correlation coefficient (r), themean andmedianRADs, and the
ISO criteria. To describe the accuracy of the measurements,
numerical point accuracy was evaluated using the median
RAD (interquartile range) and the ISO criteria. The RAD was
computed as the absolute value of the difference between the
glucose levels estimated by the RTCGMS and ABG values,
expressed as a percentage of the ABG values (Eq. 1):
RAD¼

 
ABGiRTCGMSi
ABGi
!· 100 (1)
The ISO criteria included the percentage of RTCGMS readings
within 15mg/dL of the ABG readings when the ABG reading
is £ 75mg/dL or within 20.0% of the ABG readings when the
ABC reading is > 75mg/dL.30
All of the data were reviewed for normality using the
Shapiro–Wilk and Kolmogorov–Smirnov tests. Analysis of
variance was used to determine differences between the
numbers of reference measurements performed per hour in
each of the groups. For data that did not follow a normal
distribution, nonparametric contrast techniques were used.
The Wilcoxon signed-rank test was used to compare median
RADs and to determine whether there were any statistically
significant differences in accuracy. The Kruskal–Wallis test
was used to determine significant differences between the
glycemic ranges in each of the groups. Two-sided tests were
used, and a= 0.05 was considered to be the threshold of sig-
nificance. Analyses were performed using SPSS for Windows
(SPSS Institute, Chicago, IL).
In addition, a Bland–Altman analysis with limits of agree-
ment was used to assess the accord between the measure-
ments.39 The Bland–Altman analysis plotted the differences
between the ABG and RTCGMS (y-axis) against the means of
the ABG and RTCGMS (x-axis).
Results
In total, 956 paired ABG/RTCGMS data points were ob-
tained from all the patients who participated in the study. The
Pearson correlation coefficient between the RTCGMS and
ABG values was 0.7 (P < 0.05). The median RTCGMS was 128
(108–154) mg/dL, and the median ABG was 136 (120–156)
mg/dL. Table 2 shows the overall median RAD and the
measurements that fulfilled the ISO criteria for all data points.
Assessment using numerical point accuracy of the
RTCGMS according to the septic status of the patient (patients
with septic shock, with sepsis, and without sepsis) was also
calculated (Table 2). In patients with septic shock, the median
RTCGMS was 130 (110–158) mg/dL, whereas the median
ABG was 136 (118–154) mg/dL. For patients with sepsis, the
median RTCGMS was 124 (103–152) mg/dL, and the median
ABG was 135 (120–155) mg/dL. For patients without sepsis,
the median RTCGMS was 130 (108–154) mg/dL, and the
median ABG was 138 (121–158) mg/dL. According to a
Kruskal–Wallis test, the glycemic ranges of ABG measure-
ments for each of the three groups were similar (P > 0.05),
without significant differences among them. The median
RAD values in patients with septic shock were significantly
more accurate than the median RAD values in patients with
sepsis (P = 0.003). When comparing patients with septic shock
and patients without sepsis, significant differences in the
median RAD values between the two cohorts were detected
(P= 0.001). Moreover, the Bland–Altman plot also showed the
accuracy of the RTCGMS in relation to ABG values (Fig. 1).
Table 2. Numerical Point Accuracy
RTCGMS
(mg/dL)
ABG
(mg/dL)
ABG calibration
(mg/dL) RAD (%)
ISO
criteria (%)
Total reference
readings
Number
of measurements
per hour
Overall 128 (108–154) 136 (120–156) 130 (116–147) 13.5 (6.0–24.1) 68.1 956 —
With septic shock 130 (110–158) 136 (118–154) 132 (117–147) 11.2 (5.4–20.5) 74.5 326 0.43 (0.36–0.60)
With sepsis 124 (103–152) 135 (120–155) 128 (113–144) 14.3 (6.7–26.9) 65.6 360 0.40 (0.30–0.55)
Without sepsis 130 (108–154) 138 (121–158) 138 (114–156) 16.3 (6.3–25.6) 63.7 270 0.50 (0.35–0.60)
Data are median values. Numbers in parentheses indicated the interquartile range (Q1–Q3, respectively).
ABG, arterial blood glucose; ISO, International Organization for Standardization; RAD, relative absolute difference; RTCGMS, real-time
continuous glucose monitoring system.
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Furthermore, 493 ABG measurements were used for
RTCGMS calibration, resulting in 12 samples per patient on
average. Median glucose measured during calibration was
132 (117–147) mg/dL for patients with septic shock, 128 (113–
144) mg/dL for patients with sepsis, and 138 (114–156) mg/dL
for patients without sepsis. So, the glycemic range of cali-
bration measurements for each of the three groups was sim-
ilar (P > 0.05), without significant differences among them
(according to a Kruskal–Wallis test). ABGmeasurements used
for calibration were within the range considered correct ac-
cording to our protocol (Table 2).
The number of reference measurements performed per
hour was not statistically different among the three groups
(P > 0.05). A median of 0.43 (0.36–0.60) ABG samples per hour
was performed in the septic shock group, whereas medians
of 0.40 (0.30–0.55) and 0.50 (0.35–0.60) ABG samples per
hour were found in the sepsis and without sepsis groups,
respectively.
Numerical point accuracy of the overall data was also
calculated by glucose ranges (27 data pairs were below
80mg/dL, 727 were between 80 to 160mg/dL and 202 were
above 160mg/dL). The results showed that the RTCGMSwas
equally accurate for patients with normoglycemia and hy-
perglycemia (median RAD of 13.9% [6.0–23.7%] and ISO
criteria of 68.8%; median RAD of 12.0% [6.0–24.1%] and ISO
criteria of 67.8%, respectively). The RTCGMS was less accu-
rate in the hypoglycemic range (median RAD of 15.0% [4.2–
27.3%] and ISO criteria of 51.9%).
Finally, numerical point accuracy metrics were also calcu-
lated according to the cause of the patient’s critically ill status
(370 medical data pairs, 433 surgical data pairs, and 153
trauma data pairs were analyzed). In agreement with the
expected results, there were no significant differences in ac-
curacy between the medical and surgical patients (P > 0.05).
When comparing the medical cohort (median RAD of 14.5%
[6.6–25.0%] with ISO criteria of 67.0%) and the surgical cohort
(median RAD of 11.7% [5.4–22.4%]with ISO criteria of 71.1%),
similar numerical accuracy metrics were obtained. The trau-
ma patients were not compared because of the insufficient
size of this cohort (median RADof 15.5% [7.0–28.3%]with ISO
criteria of 62.1%).
Discussion
The numerical and clinical accuracy results obtained in this
study are similar to those of previously reported studies on
critically ill patients.18–23 These results also demonstrate that
the type of critically ill patient (i.e., medical, surgical, or
trauma) does not have a significant influence on the accuracy
of the CGMS. Furthermore, the accuracy of the CGMS in the
ICU was similar to that seen in patients with type 1 diabetes
mellitus.40–42 Consistent with these studies,18–21,23 we also
conclude that although the CGMS could be clinically useful in
the ICU, it is not sufficiently accurate and reliable at present to
be used for therapeutic decisions.
The determination of interstitial glucose showed greater
accuracy in patients with septic shock. Patients with sepsis
or septic shock are the most frequently admitted to the
ICU. In this type of ICU patient, the BG values are usually
in the hyperglycemic range, and glycemic control is often
more difficult than in patients without sepsis.5–9 For this
reason, international guidelines for the management of
sepsis and septic shock recommend the practice of gly-
cemic control.35
Previously, other authors have observed similar phenom-
ena and reported better accuracy using CGMS devices in
patients with septic shock,21 in pediatric patients with ino-
tropic support,22 and in pediatric patients with support
measures (such as mechanical ventilation or vasopressor
use),26 although their data did not achieve statistical signifi-
cance. This phenomenon could be caused by the increase in
capillary permeability seen in patients with septic shock. This
increase in capillary permeability would result in an increase
in the diffusion of the intravascular glucose to the interstitial
space. Consequently, the lag time to reach the equilibrium
between ABG and interstitial glucose may be smaller, which
would improvement the accuracy of the RTCGMS.
In contrast, a recent study did not discover any differences
in the accuracy of the CGMS in patients with inotropic sup-
port27; however, the average dose of norepinephrine admin-
istered in this study was quite low (0.04 lg/kg/min), and the
indication for administering norepinephrine was not clear.
Calibrations over a different range would potentially yield
different sensor readings and thus potentially different accu-
racies. In our study similar calibration ranges between groups
have been used, and therefore outcomes have not been
influenced by this fact.
Furthermore, no local complications (e.g., local infection,
inflammation, or bleeding) resulted from the placement of the
subcutaneous sensors.
The CGMS is a potential tool to provide detailed informa-
tion about glucose levels. The potential benefits of the use of
the CGMS would be avoiding multiple blood draws from the
patient. In addition, the patient would avoid the frequent,
uncomfortable, and painful punctures on the digital pad or
earlobe associated with capillary BG. Other benefits of using
the CGMS would be a reduction in the workload of nurses
and a reduction in the risk of accidental puncture. However,
there are other aspects that could hinder the routine use of
CGMS in the ICU. It is necessary to provide specific training to
the nursing and other ICU staff on the effective use of such
systems. Finally, the high cost to implement this technology in
the ICU must be taken into account.
In conclusion, the accuracy of the RTCGMS was similar to
that reported in other studies in critically ill patients. Equally
important is that the results showed that the septic status of
the patient influenced the accuracy of the RTCGMS in the ICU.
However, it is important tohighlight that the studyonly focused
on one specific CGMS, one based on a subcutaneous sensor
in order tomeasure interstitial glucose concentration. Therefore,
it is not possible to extrapolate the results for other glucose
sensor technologies, especially for intravenous methods.
Accuracy was significantly better in the patients with septic
shock compared with other patient cohorts. Therefore, the
accuracy of the RTCGMS was not worse in patients with
septic shock, who have the worst state of interstitial tissue
perfusion. Further research is needed to confirm the predicted
benefits of continuous glucose monitoring compared with
standard monitoring in this type of critically ill patient.
Study limitations
Our study has some technical limitations. First, although
statistically significant differences have been achieved in our
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samples, future studies with a larger sample size are required.
These analyses should focus on the use of the CGMS
according to the septic status of the patient. Moreover, hy-
poglycemic events were very infrequent. For this reason, it
was difficult to draw conclusions on the performance of the
RTCGMS in the hypoglycemic range. In our ICU, hypogly-
cemic events are very infrequent because of the glycemic
control protocol, not designed for tight glycemic control but to
avoid hypoglycemia.
Second, in our study we observed a better accuracy of the
RTCGMS in septic shock. The use of norepinephrine was re-
corded qualitatively but not the dose of inotropes needed in
each case and the time that the patients needed them. In future
studies, it would be interesting to assess if the accuracy of the
RTCGMS varies depending on the dose of vasopressors.
Other factors that could be interesting in assessing the accu-
racy of the RTCGMS, such as the use of glucocorticoids or the
fluid balance, were not recorded.
Third, we did not consider other factors that could influ-
ence significantly the accuracy of the RTCGMS in critically ill
patients, such as the degree of edema or the level of tissue
perfusion (assessed by measuring the lactate concentration).
Fourth, although the results of the RTCGMS were not
compared with the reference values obtained in a laboratory
test or with a blood gas analyzer, they were compared against
the device used in the ICU. ABG samples were determined
with the HemoCue in whole blood. The selection of the Hemo-
Cue was based partly on that we required more frequent
measurements of blood glucose, according to our protocol.
The HemoCue is suitable given its minimum requirements of
whole blood volume, simple calibration procedure, rapid re-
sponse, lower cost, and durability in the clinical environment.
Furthermore, HemoCue gives reliable results over a wide
range of hematocrit values.43
However, there are concerns about its accuracy.44 Whereas
previous studies had found a good correlation between the
HemoCue system and the laboratory plasma reference,45,46
another study does not recommend use of the HemoCue be-
cause its lack of accuracy compared with laboratory glucose
results.47 Moreover, this device has been also used as a ref-
erence in other important studies to analyze the glycemic
control.11,15,16 So, to avoid these concerns in future studies it
may be necessary to compare with laboratory measurements.
Fifth, we did not evaluate the accuracy of RTCGMS de-
pending on its location, because of the complexity of critically
ill patients. The placement of these sensors in other anatomical
sites, such as the abdomen, is difficult in surgical patients. Its
location in the chest is precluded because it is not rec-
ommended to expose the sensor transmitter to X-rays.37
Furthermore, critically ill patients are usually in the supine
position, and they are sedated for a long time, so it is im-
possible to locate the RTCGMS in the buttocks.
Finally, an important problem of our study has been the
long learning interval required by the nursing and other ICU
staff, to acquire the knowledge necessary for the proper use of
the sensor.
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